Q-omics provides the consensus-scored SNORA16B profile across patient tissues and cancer cell-line models. SNORA16B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SNORA16B is differentially expressed in 6, with the highest sampling consensus in CHOL. Additionally, SNORA16B RNA expression shows 18,272 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, CHOL, and UVM as cancer lineages where SNORA16B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA16B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA16B survival associations across molecular data types. SNORA16B RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA16B RNA expression–survival associations across cancer types. High SNORA16B expression shows unfavorable associations in MESO, UVM, UCEC, SKCM and CESC, but favorable associations in BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SNORA16B RNA expression.
This table summarizes SNORA16B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA16B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA16B shows lower tumor expression in LUAD, LUSC and KIRC and higher tumor expression in CHOL, LIHC and COAD. The CHOL box plot shows higher SNORA16B RNA expression in tumor versus normal tissue (log2 FC = +1.002, t-test p = .002).
This table shows molecular features associated with SNORA16B in patient tissues and cancer cell lines. In patient samples, SNORA16B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
